WO2023143610A3 - 载脂蛋白e的c端片段及其在抑制γ分泌酶酶活中的应用 - Google Patents
载脂蛋白e的c端片段及其在抑制γ分泌酶酶活中的应用 Download PDFInfo
- Publication number
- WO2023143610A3 WO2023143610A3 PCT/CN2023/073849 CN2023073849W WO2023143610A3 WO 2023143610 A3 WO2023143610 A3 WO 2023143610A3 CN 2023073849 W CN2023073849 W CN 2023073849W WO 2023143610 A3 WO2023143610 A3 WO 2023143610A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fragment
- amino acid
- apoe
- application
- acid residue
- Prior art date
Links
- 101710095339 Apolipoprotein E Proteins 0.000 title abstract 7
- 102100029470 Apolipoprotein E Human genes 0.000 title abstract 7
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title abstract 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 210000004900 c-terminal fragment Anatomy 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 6
- 125000000539 amino acid group Chemical group 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010060219 Apolipoprotein E2 Proteins 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 230000006862 enzymatic digestion Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2023213923A AU2023213923A1 (en) | 2022-01-30 | 2023-01-30 | C-TERMINAL FRAGMENT OF APOLIPOPROTEIN E AND APPLICATION THEREOF IN INHIBITING γ-SECRETASE ACTIVITY |
MX2024009427A MX2024009427A (es) | 2022-01-30 | 2023-01-30 | Fragmento c-terminal de apolipoproteina e y aplicacion del mismo en la inhibicion de la actividad de \03b3-secretasa. |
CN202380018990.9A CN118786138A (zh) | 2022-01-30 | 2023-01-30 | 载脂蛋白E的C端片段及其在抑制γ分泌酶酶活中的应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210113320.2 | 2022-01-30 | ||
CN202210113320.2A CN116554303A (zh) | 2022-01-30 | 2022-01-30 | 载脂蛋白E的C端片段及其在抑制γ分泌酶酶活中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023143610A2 WO2023143610A2 (zh) | 2023-08-03 |
WO2023143610A3 true WO2023143610A3 (zh) | 2023-10-26 |
Family
ID=87470769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/073849 WO2023143610A2 (zh) | 2022-01-30 | 2023-01-30 | 载脂蛋白e的c端片段及其在抑制γ分泌酶酶活中的应用 |
Country Status (4)
Country | Link |
---|---|
CN (2) | CN116554303A (zh) |
AU (1) | AU2023213923A1 (zh) |
MX (1) | MX2024009427A (zh) |
WO (1) | WO2023143610A2 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020147999A1 (en) * | 2000-11-03 | 2002-10-10 | Yadong Huang | Methods of treating disorders related to apoE |
US20050202532A1 (en) * | 2002-05-08 | 2005-09-15 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
US20100204103A1 (en) * | 2002-05-08 | 2010-08-12 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
-
2022
- 2022-01-30 CN CN202210113320.2A patent/CN116554303A/zh active Pending
-
2023
- 2023-01-30 AU AU2023213923A patent/AU2023213923A1/en active Pending
- 2023-01-30 WO PCT/CN2023/073849 patent/WO2023143610A2/zh active Application Filing
- 2023-01-30 MX MX2024009427A patent/MX2024009427A/es unknown
- 2023-01-30 CN CN202380018990.9A patent/CN118786138A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020147999A1 (en) * | 2000-11-03 | 2002-10-10 | Yadong Huang | Methods of treating disorders related to apoE |
US20050202532A1 (en) * | 2002-05-08 | 2005-09-15 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
US20100204103A1 (en) * | 2002-05-08 | 2010-08-12 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
Non-Patent Citations (2)
Title |
---|
CHARULATHA VEDHACHALAM ET AL.: "The C-Terminal Lipid-Binding Domain of Apolipoprotein E Is a Highly Efficient Mediator of ABCA1-Dependent Cholesterol Efflux that Promotes the Assembly of High-Density Lipoproteins", BIOCHEMISTRY, vol. 46, no. 10, 17 February 2007 (2007-02-17), pages 2583 - 2593, XP008138940, DOI: 10.1021/bi602407r * |
XIONG, HUAQI ET AL.: "Cholesterol Retention in Alzheimer's Brain Is Responsible for High (3- and gamma-secretase Activities and A(3 Production", NEUROBIOL DIS., vol. 29, no. 3, 31 March 2008 (2008-03-31), pages 422 - 437, XP022492237, DOI: 10.1016/j.nbd.2007.10.005 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023143610A2 (zh) | 2023-08-03 |
MX2024009427A (es) | 2024-08-14 |
CN118786138A (zh) | 2024-10-15 |
CN116554303A (zh) | 2023-08-08 |
AU2023213923A1 (en) | 2024-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ606427A (en) | Extended recombinant polypeptides and compositions comprising same | |
Wendt et al. | Interaction of calpastatin with calpain: a review | |
Ugai et al. | Purification and characterization of the 26S proteasome complex catalyzing ATP-dependent breakdown of ubiquitin-ligated prot from rat liver | |
Abreu et al. | Peptidomics of Acanthoscurria gomesiana spider venom reveals new toxins with potential antimicrobial activity | |
DE60310264D1 (en) | Thermostabile alpha-amylase | |
Inzitari et al. | Detection in human saliva of different statherin and P‐B fragments and derivatives | |
NZ595499A (en) | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them | |
NZ596764A (en) | N-glycan core beta-galactosyltransferase and uses thereof | |
Sasaki | Patchwork‐structure serpins from silkworm (Bombyx mori) larval hemolymph | |
LaFayette et al. | Molecular characterization of cDNAs encoding low-molecular-weight heat shock proteins of soybean | |
Bolscher et al. | A one-enzyme strategy to release an antimicrobial peptide from the LFampin-domain of bovine lactoferrin | |
WO2010007144A3 (en) | Mutated netrin-4 proteins, fragments thereof and their uses as drugs | |
Su et al. | High-level expression and purification of human epidermal growth factor with SUMO fusion in Escherichia coli | |
MX2022009515A (es) | Variantes de alfa-amilasa y polinucleotidos que las codifican. | |
WO2007142582A8 (en) | Fluorescent proteins and genes encoding them | |
Pérez‐Peinado et al. | Structural determinants conferring unusual long life in human serum to rattlesnake‐derived antimicrobial peptide Ctn [15‐34] | |
Imajoh et al. | Calcium-activated neutral protease inhibitor from rabbit erythrocytes lacks the N-terminal region of the liver inhibitor but retains three inhibitory units | |
Chessa et al. | Synthetic peptides reproducing the site phosphorylated by cAMP‐dependent protein kinase in protein phosphatase inhibitor‐1: Effect of structural modifications on the phosphorylation efficiency | |
Dohmae et al. | The complete amino acid sequences of two serine proteinase inhibitors from the fruiting bodies of a basidiomycete, Pleurotus ostreatus | |
WO2023143610A3 (zh) | 载脂蛋白e的c端片段及其在抑制γ分泌酶酶活中的应用 | |
IL168793A (en) | Streptococcus uberis adhesion molecule | |
Saitoh et al. | Production and characterization of two variants of human cystatin SA encoded by two alleles at theCST2Locus of the type 2 cystatin Gene family | |
Hartmann et al. | Heterodimeric capping proteins constitute a highly conserved group of actin‐binding proteins | |
WO2022031733A3 (en) | Keratinolytic polypeptides and methods of use | |
CN112481286A (zh) | 提高重组牛奶蛋白异源表达效率的氨基酸序列 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23746487 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2024/009427 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024015617 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2023213923 Country of ref document: AU Date of ref document: 20230130 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023746487 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2023746487 Country of ref document: EP Effective date: 20240830 |